Masuda, N.
Toi, M.
Yamamoto, N.
Iwata, H.
Kuroi, K.
Bando, H.
Ohtani, S.
Takano, T.
Inoue, K.
Yanagita, Y.
Kasai, H.
Morita, S.
Sakurai, T.
Ohno, S.
Funding for this research was provided by:
Japan Breast Cancer Research Group
GlaxoSmithKline
Kyoto University
Article History
Received: 17 October 2017
Accepted: 21 January 2018
First Online: 14 February 2018
Compliance with ethical standards
:
: Norikazu Masuda reports personal fees (honoraria) from Chugai and AstraZeneca outside the submitted work. Masakazu Toi is currently conducting research sponsored by Novartis. Naohito Yamamoto reports research funding from Pfizer, GlaxoSmithKline, and AstraZeneca. Hiroji Iwata received honoraria from Chugai and GlaxoSmithKline. Katsumasa Kuroi, Hiroko Bando, Shoichiro Ohtani, Kenichi Inoue, Yasuhiro Yanagita, Hiroi Kasai, and Takaki Sakurai have nothing to disclose. Toshimi Takano is currently conducting research sponsored by Chugai and Novartis. Satoshi Morita received an honorarium from Chugai. Shinji Ohno received speaker’s bureau fees from Chugai, AstraZeneca, and Eisai.